ArticleTranslational lung cancer research2025
O-GlcNAcylation levels predict radiotherapy outcome in non-small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- O-GlcNAcylation at the tumor-immune interface: a metabolic post-translational code driving immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited evidence exists on the role of protein glycosylation, particularly O-GlcNAcylation (O-GlcNAc), in predicting radiotherapy (RT) response in non-small cell lung cancer (NSCLC). This study aimed to investigate O-GlcNAc expression, glucose metabolism indicators, and their associations with RT response and prognosis in NSCLC. Methods: We conducted a retrospective cohort study of 216 NSCLC patients who underwent RT and positron emission tomography-computed tomography (PET-CT) imaging. O-GlcNAc expression in pretreatment primary tumor specimens was evaluated by immunohistochemistry (IHC), and patients were categorized into high- and low-expression groups. All patients were matched for age, sex, diagnosis, and pathological stage. Clinical features were reviewed, and multivariable logistic regression was applied to analyze associations between O-GlcNAc levels and clinical parameters. The conditional logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs). Kaplan-Meier analysis was performed to evaluate the prognostic impact of O-GlcNAc expression. Pretreatment blood glucose levels and primary tumor glucose uptake [maximum standardized uptake value (SUVmax)] from PET-CT were also assessed, and correlation analyses were conducted to determine their relationships with RT response and survival outcomes. Results: Low O-GlcNAc expression was independently associated with poor RT response (P=0.005; OR =2.47; 95% CI: 1.32-4.64) and significantly predicted shorter progression-free survival (PFS; log-rank P=0.049) and overall survival (OS; log-rank P=0.008). In contrast, blood glucose levels (P=0.59) and primary tumor SUVmax (P=0.38) showed no association with RT response, and neither blood glucose nor SUVmax correlated with PFS; however, high SUVmax was predictive of shorter OS (log-rank P=0.03). Conclusions: High O-GlcNAc expression was a predictor of favorable RT response and improved PFS and OS in NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.